Ian Cooper

Ian Cooper

InvestorPlace Contributor

Ian Cooper has helped traders grow and protect their wealth since 1999.

Over the last 24 years, he’s taught thousands of investors how to trade news flow and herd mentality using a unique blend of technical and fundamental analysis. In fact, Cooper created the ADD News Flow Strategy, which allows us to trade the anticipation, dissemination, and the death of news flow by exploiting herd mentality.

Cooper was among the few analysts to spot the financial crisis of 2008, the top of subprime and Alt-A, the death of Lehman Brothers, Bear Stearns, and New Century Financial, and even the Dow’s collapse to 6,500, as well as its recovery. He even called for gold to rally well above $1.500 when it traded under $600.

At the moment, Cooper makes use of technical, fundamental and news analysis, to help individual investors grow their wealth. He’s a firm believer that hard work and thorough research will lead to investment success.

Recent Articles

Advanced Micro Devices Could Still Soar to $100. Here’s Why.

By Ian Cooper, InvestorPlace Contributor

With plenty of near-term catalysts, use every pullback by AMD stock as an opportunity to buy more of its shares.

3 Cheap Stocks to Buy for Under $5 Now

By Ian Cooper, InvestorPlace Contributor

Spot the best cheap stocks to buy under $5 with the right catalyst at the right time, and it could lead to your next double-digit opportunity.

The Key Reasons Investors Should Avoid Inovio Pharmaceuticals Stock

By Ian Cooper, InvestorPlace Contributor

The first time I highlighted opportunity in Inovio Pharmaceuticals (NASDAQ:INO), it traded at just $4.86 a share. That was in late January. By July, the…

Keep Buying Facebook Stock on the Dip for the Foreseeable Future

By Ian Cooper, InvestorPlace Contributor

Long-term, I think Facebook is the next $1 trillion stock. Near-term, FB stock could move lower after becoming a bit overbought.

It’s Best to Avoid Ocugen Stock at the Moment

By Ian Cooper, InvestorPlace Contributor

Until we begin to see solid trial results, OCGN stock could easily plunge back to 20 cents a share. Avoid investing in Ocugen for now.

Load More